http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
대량객혈로 내원하여 폐결핵에 의한 폐동맥기관지루로 진단된
조경욱 ( Kyung Wook Jo ),홍윤기 ( Yoon Ki Hong ),한정혜 ( Jung Hye Han ),이재근 ( Jae Keun Lee ),홍상범 ( Sang Bum Hong ) 대한결핵 및 호흡기학회 2007 Tuberculosis and Respiratory Diseases Vol.63 No.5
Massive and untreated hemoptysis is associated with a >50% mortality rate. Since bleeding has a bronchial arterial origin in most patients, bronchial artery embolization (BAE) has become an accepted treatment in massive hemoptysis. The possibility of bleeding from pulmonary artery should be considered in patients in whom the bleeding focus cannot be found by Bronchial angiogram. Indeed, the bleeding occurs from a pulmonary artery in approximately 10% of patients with massive hemoptysis. The most common causes of bleeding from the pulmonary artery are pulmonary artery rupture associated with a Swan-Ganz catheter, infectious diseases and vasculitis. We report a rare case of a fistula between the right upper lobar pulmonary artery and the right upper lobar bronchus in a 71-year-old woman who presented with massive hemoptysis. (Tuberc Respir Dis 2007;63:430-434)
다제내성 폐결핵 환자의 베다퀼린과 델라마니드 동시, 장기간 사용 1예
현동곤 ( Dong-gon Hyun ),이세희 ( Se Hee Lee ),조경욱 ( Kyung-wook Jo ),심태선 ( Tae Sun Shim ) 대한내과학회 2019 대한내과학회지 Vol.94 No.3
Bedaquiline and delamanid were recently approved for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Korea. A treatment duration of 24 weeks was established based on phase 2 clinical trial data, although the combined use of these two drugs is typically not recommended because it may exaggerate QT prolongation. Here, we present a case of prolonged treatment (48 weeks) with a combination of bedaquiline and delamanid for pulmonary MDR-TB. The patient had previously been diagnosed with extensively drug-resistant TB but had been left untreated for the past 9 years due to a shortage of effective drugs. A combination of bedaquiline and delamanid successfully treated MDR-TB, highlighting the potential efficacy of these drugs for patients with drug-resistant TB infections. (Korean J Med 2019;94:294-298)
호습기 크론병 환자에서 종양 괴사 인자 길항제 재시작 후 재발한 결핵
박소정 ( Sojung Park ),양지영 ( Ji Young Yang ),송민주 ( Min Joo Song ),천재경 ( Jaekyung Cheon ),김수한 ( Soo Han Kim ),김미진 ( Mi Jin Kim ),조경욱 ( Kyung Wook Jo ) 대한내과학회 2015 대한내과학회지 Vol.88 No.6
The use of tumor necrosis factor inhibitors (TNFi) increases a patient’s risk of developing tuberculosis (TB). There is no consensus on whether restarting a TNFi after treating an active TB infection caused by previous TNFi exposure is safe. We report the first case of TB recurrence after recommencing a TNFi in a 37-year-old woman with a history of active TB infection caused by previous TNFi treatment. (Korean J Med 2015;88:701-705)